Vor Biopharma Inc. (VOR) Financial Statements
Free cash flow over the same period: -$140.8M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
VORVor Biopharma Inc.Follow VOR — free
—
Price chart with a free account
- Market cap
- 1.1B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Research & development | 47.5 | 64.6 | 94.3 | 93.3 | 321.5 | 76.8 | |
| Operating income | -69.0 | -93.4 | -126.0 | -121.2 | -371.6 | -147.1 | |
| Pre-tax income | -68.9 | -92.1 | -117.9 | -116.9 | -696.0 | 627.8 | |
| Net income | -68.9 | -92.1 | -117.9 | -116.9 | -696.0 | 627.8 | |
| Diluted EPS ($) | -2.10 | -46.60 | -35.00 | -34.03 | -70.50 | 11.55 | |
| Diluted shares (mn) | — | 2.0 | 3.4 | 3.4 | 9.9 | — |
USD millions · SEC XBRL
Vor Biopharma Inc. — questions
- What is Vor Biopharma Inc.'s net income?
- $627.8M over the twelve months to 2026-06-30.
- What is Vor Biopharma Inc.'s free cash flow?
- -$140.8M over the twelve months to 2026-06-30.
- What are Vor Biopharma Inc.'s diluted earnings per share?
- $11.55 over the twelve months to 2026-06-30.
Every figure on this page comes from Vor Biopharma Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.